Royal Bank of Canada
REGN icon

Royal Bank of Canada’s Regeneron Pharmaceuticals REGN Stock Holding History

Royal Bank of Canada’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-200
Closed -$192K – 7451
2024
Q1 		$192K Buy
+200
New +$190K ﹤0.01% 4729
2023
Q2 		– Sell
-5,500
Closed -$4.52M – 7588
2023
Q1 		$4.52M Buy
+5,500
New +$4.15M ﹤0.01% 2156
2016
Q2 		– Sell
-25,000
Closed -$9.01M – 6497
2016
Q1 		$9.01M Buy
+25,000
New +$10.3M 0.01% 1448

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Royal Bank of Canada's REGN Position: Q1 2026 in Review

Royal Bank of Canada increased its Regeneron Pharmaceuticals (REGN) stake by 1.7% in Q1 2026, buying an estimated $4.56M and bringing the position to 351,171 shares worth $271M. The position accounts for 0.05% of the portfolio, ranked #339.

Royal Bank of Canada first reported a position in REGN in Q2 2013 and has held it in 52 quarters since. The position peaked at $275M in Q3 2024. 1,396 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Royal Bank of Canada held 351,171 shares of Regeneron Pharmaceuticals worth $271M as of Q1 2026.
  • Royal Bank of Canada bought 5,952 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $4.56M.
  • Regeneron Pharmaceuticals made up 0.05% of Royal Bank of Canada's portfolio in Q1 2026, its #339 holding.
  • Royal Bank of Canada first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Royal Bank of Canada's Regeneron Pharmaceuticals position peaked at $275M in Q3 2024.
  • 1,396 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.